1,290 reports of this reaction
5.1% of all RITONAVIR 100 MG reports
#2 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #2 most commonly reported adverse reaction for RITONAVIR 100 MG, manufactured by Cipla USA Inc.. There are 1,290 FDA adverse event reports linking RITONAVIR 100 MG to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 5.1% of all 25,519 adverse event reports for this drug.
Patients taking RITONAVIR 100 MG who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is moderately reported among RITONAVIR 100 MG users, representing a notable but not dominant share of adverse events.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for RITONAVIR 100 MG:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 1,290 FDA reports for RITONAVIR 100 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 5.1% of all adverse event reports for RITONAVIR 100 MG, making it one of the most commonly reported side effect.
If you experience foetal exposure during pregnancy while taking RITONAVIR 100 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.